Dr Brad Walsh
Founded Minomic raising over A$27 million to commercialize its first major product, MiCheck, as well as developing a pipeline of new diagnostics for other cancers.
He has a PhD in protein chemistry and has led research groups in government agencies, universities and hospitals.
Dr Walsh was a key part of the establishment of a major national research facility before forming Minomic in 2007. He has a long history of commercialization and his products are being sold by major corporations, such as Bio-Rad Laboratories.
CFO / Company Secretary
Is a seasoned financial professional having worked in the chemical, telecommunications, and financial services industries.
He has held various senior/board positions, for both listed and unlisted companies, in Australia, the UK and Hong Kong, including Swire Blanch Limited and OAMPS Limited.
His extensive consulting background includes provision of services to industry and government as well as expert witness evidence.
Dr Douglas Campbell
Head of Research and Development
Leads Minomic’s scientific team. He has been instrumental in building Minomic’s intellectual property estate and designing all the clinical trials.
Dr Campbell has nearly 20 years of experience in biomedical research with a particular focus on oncology. Prior to Minomic he was involved in the development of a novel antibody (MDX-1097) from pre-clinical to Phase 2 clinical trials.
Chief Commercialization Officer
David has 20 years of experience in managing multi-million dollar sales budgets within multinational diagnostics corporations including Roche, Becton Dickinson and Bio-Rad Laboratories.
He has a strong track record in developing strategic plans and has had full P&L responsibility, created high performance teams and led transformations to deliver growth well beyond market rates.
Is a global marketing and sales strategist with over 15 years of healthcare experience, spanning clinical diagnostics, LDTs, point-of-care medical devices, e-health, and distribution.
At Focus Diagnostics, a subsidiary of Quest Diagnostics, launched a molecular platform along with 3 FDA cleared assays, 8 CE kits and 20 ASRs for the development of LDTs. She established a consulting firm in 2014, collaborating with emerging technologies to establish strong clinical relationships to drive early adoption and product roadmaps for commercialization.
Dr Yanling Lu
Head of CMC (Chemistry, Manufacturing and Control)
Over 15 years’ experience in the biotech and medtech industries specialising in product development and assay validation.
In 2016 Dr Lu moved to Clinical Genomics, leading the analytical validation of CG’s new product InSureOne™ which was a key to its successful FDA 510(k) approval.
She was involved in the technology transfer of CG’s diagnostic test into their CLIA laboratory at Bridgewater (NJ). She is also conversant with regulatory guidelines (FDA, EMA, ICH, TGA and CLSI etc).
Dr Maria Lund
Pancreatic Cancer Lead
Completed her PhD in Immunology at the University of Technology Sydney. Her doctoral work identified a novel peptide therapeutic for autoimmune disease, which led to the spin out of a company to commercialise this.
Moving to the diagnostic sector in 2016, Dr Lund contributed to the development of the MiCheck multianalyte diagnostic test for prostate cancer, and several pipeline diagnostic tests. Her role spanned the development and validation of the platform, biomarker discovery, through to validation of test performance in patient samples. She has extensive understanding of clinical guidelines and experience in clinical trial design.